Cannabis sativa CBD Extract Shows Promising Antibacterial Activity against Salmonella typhimurium and S. newington

Molecules. 2022 Apr 21;27(9):2669. doi: 10.3390/molecules27092669.


Products derived from Cannabis sativa L. have gained increased interest and popularity. As these products become common amongst the public, the health and potential therapeutic values associated with hemp have become a premier focus of research. While the psychoactive and medicinal properties of Cannabis products have been extensively highlighted in the literature, the antibacterial properties of cannabidiol (CBD) have not been explored in depth. This research serves to examine the antibacterial potential of CBD against Salmonella newington and S. typhimurium. In this study, we observed bacterial response to CBD exposure through biological assays, bacterial kinetics, and fluorescence microscopy. Additionally, comparative studies between CBD and ampicillin were conducted against S. typhimurium and S. newington to determine comparative efficacy. Furthermore, we observed potential resistance development of our Salmonella spp. against CBD treatment.

Keywords: Salmonella; cannabidiol; membrane disruption; novel antibacterial agents.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cannabidiol* / pharmacology
  • Cannabinoids* / therapeutic use
  • Cannabis*
  • Plant Extracts / pharmacology
  • Salmonella typhimurium


  • Anti-Bacterial Agents
  • Cannabinoids
  • Plant Extracts
  • Cannabidiol

Grant support